Akeso
Tracked across 2 events · 33 articles · First seen May 25, 2026 · Last active Jun 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Akeso announced that the China — National Medical Products Administration of China has approved Gumokimab (AK111), its internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was based…
Impact: Akeso received NMPA approval for Gumokimab, strengthening its autoimmune disease portfolio and global competitiveness. This approval is a significant milestone for the company, enhancing its market position and offering a new treatment option for psoriasis patients.
Jun 12, 2026 · 7 articles
Tech
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 29 to June 2, served as a crucial platform for major pharmaceutical and biotechnology companies to present significant advancements in…
Impact: Akeso announced that over 40 clinical studies of its oncology portfolio, including data on cadonilimab and ivonescimab, were presented at the 2026 ASCO Annual Meeting, with one Late-Breaking Abstract selected for a Plenary Session.
May 25, 2026 · 26 articles
100
Akeso presented Phase III results IvonescimabASCO 2026 Oncology Data...
90
Akeso developed GumokimabAkeso's gumokimab approved in China
85
Akeso presented clinical data CadonilimabASCO 2026 Oncology Data...
80
Akeso announced presentations American Society of Clinical OncologyASCO 2026 Oncology Data...
70
Akeso presented data LigufalimabASCO 2026 Oncology Data...
NEWSDESK
Track Akeso live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard